Valiance Asset Management

Valiance Asset Management Limited is a private equity firm founded in August 2008, headquartered in London, United Kingdom, with an additional office in Guernsey, Channel Islands. The firm specializes in direct and fund of fund investments, primarily focusing on growth capital in the life sciences and agriculture sectors, particularly in medtech, digital health, and nutritional health. Valiance also emphasizes investments in real assets and large-scale commercial farmland acquisition, with an interest in opportunities in Brazil. The firm seeks to engage in pre-merger and acquisition as well as pre-IPO opportunities, often securing board positions and taking minority stakes in its investee companies. Additionally, Valiance is involved in food production and the transformation of farmland.

Jan Pensaert

Founder and Managing Partner

10 past transactions

JenaValve Technology

Series C in 2022
JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

Laminate Medical Technologies

Venture Round in 2019
Laminate Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, founded in 2012. The company specializes in developing innovative systems to enhance vascular access for hemodialysis patients. Its flagship product, the VasQ device, is an implanted external support system designed for arteriovenous fistulas. This device is integrated during the surgical creation of the fistula and addresses critical issues such as wall tension and geometric configuration, which can lead to narrowing and blockages within the first year post-surgery. By improving the patency rates of vascular access, Laminate Medical Technologies aims to significantly reduce the failure rate of fistulas, thereby minimizing kidney-failure-related complications and the associated costs of re-interventions.

MyoScience

Venture Round in 2018
MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

FEops

Series B in 2017
FEops is a pioneering company specializing in physics-based simulations for minimally invasive cardiovascular devices and procedures. It develops advanced cardiac imaging technology that enhances personalized treatment for patients with structural heart disease. By providing artificial intelligence-enabled anatomical analyses, FEops generates data-driven insights that facilitate improvements in transcatheter valve procedures. The company collaborates with medical device developers and healthcare professionals, offering valuable simulations that accelerate research and development processes while ensuring device safety. Physicians benefit from these patient-specific insights, which enhance their efficiency and ultimately lead to improved clinical outcomes and patient safety.

NeoSync

Series D in 2017
NeoSync is a clinical-stage company focused on developing advanced, non-invasive neuromodulation products aimed at treating Major Depressive Disorder and various Central Nervous System diseases, including Autism, Parkinson's Disease, Anxiety, and Post-Traumatic Stress Disorder. The company utilizes a proprietary platform technology that employs Transcranial Magnetic Stimulation (TMS), a non-invasive brain stimulation method that delivers low-energy, alternating magnetic fields during daily 30-minute sessions. This approach is designed to gently recalibrate brain function in individuals suffering from major depressive disorders, facilitating quicker recovery and improved mental health outcomes. NeoSync is guided by a team of seasoned medical device executives and entrepreneurs, positioning the company to make significant advancements in mental health therapies.

JenaValve Technology

Series C in 2014
JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

Biocartis

Series E in 2013
Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

MyoScience

Series E in 2013
MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

MDxHealth

Post in 2013
MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced epigenetic tests to assist in the detection and treatment of cancer. The company's product portfolio includes ConfirmMDx, a prostate cancer test aimed at addressing false-negative biopsy concerns; SelectMDx, which guides repeat biopsies for prostate cancer; AssureMDx, a noninvasive liquid biopsy test for bladder cancer; and PredictMDx for Glioblastoma, a tissue methylation test that aids in treatment decisions for brain cancer. Established in 2003 and headquartered in Irvine, California, with additional offices in Belgium and the Netherlands, MDxHealth leverages proprietary genomic and epigenetic technologies to provide actionable diagnostic information. The company's revenue is generated through clinical laboratory services and out-licensing of its patented DNA methylation platform and biomarkers, serving markets primarily in the United States and Europe.

Biocartis

Series D in 2012
Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.